Literature DB >> 23264323

Blood-retinal barrier.

José Cunha-Vaz1, Rui Bernardes, Conceição Lobo.   

Abstract

The blood-ocular barrier system is formed by 2 main barriers: the blood-aqueous barrier and the blood-retinal barrier (BRB). The BRB is particularly tight and restrictive and is a physiologic barrier that regulates ion, protein, and water flux into and out of the retina. The BRB consists of inner and outer components, the inner BRB being formed of tight junctions between retinal capillary endothelial cells and the outer BRB of tight junctions between retinal pigment epithelial cells. The BRB is essential to maintaining the eye as a privileged site and is essential for normal visual function. Methods of clinical evaluation of the BRB are reviewed and new directions using optical coherence tomography are presented. Alterations of the BRB play a crucial role in the development of retinal diseases. The 2 most frequent and relevant retinal diseases, diabetic retinopathy and age-related macular degeneration (AMD), are directly associated with alterations of the BRB. Diabetic retinopathy is initiated by an alteration of the inner BRB and neovascular AMD is a result of an alteration of the outer BRB. Macular edema is a direct result of alterations of the BRB.

Entities:  

Mesh:

Year:  2011        PMID: 23264323     DOI: 10.5301/EJO.2010.6049

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  113 in total

Review 1.  Probing Metabolism in the Intact Retina Using Stable Isotope Tracers.

Authors:  Jianhai Du; Jonathan D Linton; James B Hurley
Journal:  Methods Enzymol       Date:  2015-06-14       Impact factor: 1.600

2.  Investigation of tissue cysts in the retina in a mouse model of ocular toxoplasmosis: distribution and interaction with glial cells.

Authors:  Hyun Beom Song; Bong-Kwang Jung; Jin Hyoung Kim; Young-Ha Lee; Min-Ho Choi; Jeong Hun Kim
Journal:  Parasitol Res       Date:  2018-06-02       Impact factor: 2.289

3.  Erianin alleviates diabetic retinopathy by reducing retinal inflammation initiated by microglial cells via inhibiting hyperglycemia-mediated ERK1/2-NF-κB signaling pathway.

Authors:  Tianyu Zhang; Hao Ouyang; Xiyu Mei; Bin Lu; Zengyang Yu; Kaixian Chen; Zhengtao Wang; Lili Ji
Journal:  FASEB J       Date:  2019-07-31       Impact factor: 5.191

4.  Scutellaria barbata attenuates diabetic retinopathy by preventing retinal inflammation and the decreased expression of tight junction protein.

Authors:  Xi-Yu Mei; Ling-Yu Zhou; Tian-Yu Zhang; Bin Lu; Li-Li Ji
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

Review 5.  Advances in ocular drug delivery systems.

Authors:  Jennifer J Kang-Mieler; Kayla M Rudeen; Wenqiang Liu; William F Mieler
Journal:  Eye (Lond)       Date:  2020-02-18       Impact factor: 3.775

6.  Schizophrenia and the retina: Towards a 2020 perspective.

Authors:  Steven M Silverstein; Samantha I Fradkin; Docia L Demmin
Journal:  Schizophr Res       Date:  2019-11-07       Impact factor: 4.939

7.  Intravitreal vascular endothelial growth factor.

Authors:  Thomas Bertelmann; Stephan Schulze; Reka Bölöni; Walter Sekundo; Sebastian Irle; Thomas Stief; Stefan Mennel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-04       Impact factor: 3.117

Review 8.  Drug and gene delivery to the back of the eye: from bench to bedside.

Authors:  Cheryl L Rowe-Rendleman; Shelley A Durazo; Uday B Kompella; Kay D Rittenhouse; Adriana Di Polo; Alan L Weiner; Hans E Grossniklaus; Muna I Naash; Alfred S Lewin; Alan Horsager; Henry F Edelhauser
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-28       Impact factor: 4.799

Review 9.  Bioactive lipids and pathological retinal angiogenesis.

Authors:  Khaled Elmasry; Ahmed S Ibrahim; Samer Abdulmoneim; Mohamed Al-Shabrawey
Journal:  Br J Pharmacol       Date:  2018-11-19       Impact factor: 8.739

10.  [Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].

Authors:  Gregor Kastl
Journal:  Ophthalmologe       Date:  2019-08       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.